{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T09:54:08Z","timestamp":1792144448049,"version":"4.4.0"},"reference-count":130,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2013,10,1]],"date-time":"2013-10-01T00:00:00Z","timestamp":1380585600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,10,1]],"date-time":"2013-10-01T00:00:00Z","timestamp":1380585600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T00:00:00Z","timestamp":1692662400000},"content-version":"vor","delay-in-days":3612,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2013,10]]},"DOI":"10.1007\/s13311-013-0206-5","type":"journal-article","created":{"date-parts":[[2013,9,4]],"date-time":"2013-09-04T11:48:03Z","timestamp":1378295283000},"page":"664-676","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":78,"title":["Epigenetic Mechanisms of Neurodegeneration in Huntington's Disease"],"prefix":"10.1016","volume":"10","author":[{"given":"Junghee","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu Jin","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ki Yoon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil W.","family":"Kowall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hoon","family":"Ryu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1007\/s13311-013-0206-5_bib1","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/ng1093-168","article-title":"De novo expansion of a (CAG)n repeat in sporadic Huntington's disease","volume":"5","author":"Myers","year":"1993","journal-title":"Nat Genet"},{"key":"10.1007\/s13311-013-0206-5_bib2","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1056\/NEJM199405193302001","article-title":"A worldwide study of the Huntington's disease mutation the sensitivity and specificity of measuring CAG repeats","volume":"330","author":"Kremer","year":"1994","journal-title":"New Engl J Med"},{"key":"10.1007\/s13311-013-0206-5_bib3","first-page":"317","article-title":"On chorea","author":"Huntington","year":"1872","journal-title":"Med Surg Rep (Philadelphia)"},{"key":"10.1007\/s13311-013-0206-5_bib4","first-page":"995","article-title":"Nue anatomische befunde bei paralysis agitans und bei chronischer progressive chorea","volume":"27","author":"Jergelsma","year":"1908","journal-title":"Neurol Centralbl"},{"key":"10.1007\/s13311-013-0206-5_bib5","series-title":"Huntington's disease. Advances in neurology","first-page":"83","article-title":"Huntinton's chorea: Current neuropathological status","author":"Bruyn","year":"1979"},{"key":"10.1007\/s13311-013-0206-5_bib6","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1097\/00005072-198511000-00003","article-title":"Neuropathological classification of Huntington's disease","volume":"44","author":"Vonsattel","year":"1985","journal-title":"J Neuropath Exp Neurol"},{"key":"10.1007\/s13311-013-0206-5_bib7","series-title":"Neuropathology of dementing disorders","first-page":"219","article-title":"Huntinton's disease","author":"Kowall","year":"1998"},{"key":"10.1007\/s13311-013-0206-5_bib8","series-title":"Neurologic principles and practice","first-page":"503","article-title":"Neuropathology and pathophysiology of Huntington's disease in movement disorders","author":"Hersch","year":"2004"},{"key":"10.1007\/s13311-013-0206-5_bib9","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1126\/science.2931802","article-title":"Selective sparing of a class of striatal neurons in Huntington's disease","volume":"230","author":"Ferrante","year":"1985","journal-title":"Science"},{"key":"10.1007\/s13311-013-0206-5_bib10","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/0304-3940(86)90634-8","article-title":"Topography of encephalin, substance P and acetylcholinesterase staining in Huntington's disease striatum","volume":"71","author":"Ferrante","year":"1986","journal-title":"Neurosci Lett"},{"key":"10.1007\/s13311-013-0206-5_bib11","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1097\/00005072-198701000-00002","article-title":"Morphologic and histochemical characteristics of a spared subset of striatal neurons in Huntington's disease","volume":"1","author":"Ferrante","year":"1987","journal-title":"J Neuropathol Exp Neurol"},{"key":"10.1007\/s13311-013-0206-5_bib12","doi-asserted-by":"crossref","first-page":"3877","DOI":"10.1523\/JNEUROSCI.11-12-03877.1991","article-title":"Proliferative and degenerative changes in striatal spiny neurons in Huntington's disease: a combined study using the section-Golgi method and calbindin D28K immunocytochemistry","volume":"11","author":"Ferrante","year":"1991","journal-title":"J Neurosci"},{"key":"10.1007\/s13311-013-0206-5_bib13","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1126\/science.3155875","article-title":"Evidence for degenerative and regenerative changes in neostriatal spiny neurons in Huntington's disease","volume":"227","author":"Graveland","year":"1985","journal-title":"Science"},{"key":"10.1007\/s13311-013-0206-5_bib14","first-page":"24","article-title":"Patterns of cell loss in Huntington's disease","volume":"10","author":"Kowall","year":"1987","journal-title":"TINS"},{"key":"10.1007\/s13311-013-0206-5_bib15","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/0092-8674(93)90585-E","article-title":"A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes","volume":"72","author":"Huntington's disease Collaborative Research Group","year":"1993","journal-title":"Cell"},{"key":"10.1007\/s13311-013-0206-5_bib16","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1038\/352077a0","article-title":"Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy","volume":"352","author":"Spada","year":"1991","journal-title":"Nature"},{"key":"10.1007\/s13311-013-0206-5_bib17","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/ng0793-221","article-title":"Expansion of an unstable trinucleotide CAG repeat in spinocerebellar ataxia type 1","volume":"4","author":"Orr","year":"1993","journal-title":"Nat Genet"},{"key":"10.1007\/s13311-013-0206-5_bib18","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0896-6273(03)00569-5","article-title":"Neuropathogenic forms of huntingtin and androgen receptor inhibit fast axonal transport","volume":"40","author":"Szebenyi","year":"2003","journal-title":"Neuron"},{"key":"10.1007\/s13311-013-0206-5_bib19","doi-asserted-by":"crossref","first-page":"8195","DOI":"10.1128\/MCB.24.18.8195-8209.2004","article-title":"Mutant huntingtin impairs axonal trafficking in mammalian neurons in vivo and in vitro","volume":"24","author":"Trushina","year":"2004","journal-title":"Mol Cell Biol"},{"key":"10.1007\/s13311-013-0206-5_bib20","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0896-6273(00)80405-5","article-title":"Intranuclear neuronal inclusions: a common pathogenic mechanism for glutamine-repeat neurodegenerative diseases?","volume":"19","author":"Ross","year":"1997","journal-title":"Neuron"},{"key":"10.1007\/s13311-013-0206-5_bib21","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1126\/science.1056784","article-title":"Interference by huntingtin and atrophin-1 with CBP-mediated transcription leading to cellular toxicity","volume":"291","author":"Nucifora","year":"2001","journal-title":"Science"},{"key":"10.1007\/s13311-013-0206-5_bib22","first-page":"34","article-title":"Dysfunction of wild-type huntingtin in Huntington disease","volume":"18","author":"Cattaneo","year":"2003","journal-title":"News Physiol Sci"},{"key":"10.1007\/s13311-013-0206-5_bib23","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1046\/j.1471-4159.2003.01980.x","article-title":"Depletion of wild-type huntingtin in mouse models of neurologic diseases","volume":"87","author":"Zhang","year":"2003","journal-title":"J Neurochem"},{"key":"10.1007\/s13311-013-0206-5_bib24","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1038\/nm1066","article-title":"Protein aggregation and neurodegenerative disease","volume":"10","author":"Ross","year":"2004","journal-title":"Nat Med (Suppl.)"},{"key":"10.1007\/s13311-013-0206-5_bib25","doi-asserted-by":"crossref","unstructured":"Mangiarini L, Sathasivam K, Seller M, et al. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 87:493\u2013506.","DOI":"10.1016\/S0092-8674(00)81369-0"},{"key":"10.1007\/s13311-013-0206-5_bib26","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0092-8674(00)80623-6","article-title":"Reversal of neuropathology and motor dysfunction in a corditional model of Huntington's disease","volume":"101","author":"Yamamoto","year":"2000","journal-title":"Cell"},{"key":"10.1007\/s13311-013-0206-5_bib27","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/S0092-8674(00)80464-X","article-title":"Ectopically expressed CAG repeats cause intranuclear inclusions and a progressive late onset neurological phenotype in the mouse","volume":"91","author":"Ordway","year":"1997","journal-title":"Cell"},{"key":"10.1007\/s13311-013-0206-5_bib28","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/nrn1386","article-title":"Experimental therapeutics in transgenic mouse models of Huntington's disease","volume":"5","author":"Beal","year":"2004","journal-title":"Nat Rev Neurosci"},{"key":"10.1007\/s13311-013-0206-5_bib29","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.pharmthera.2005.04.008","article-title":"The therapeutic role of creatine in Huntington's disease","volume":"108","author":"Ryu","year":"2005","journal-title":"Pharmacol Ther"},{"key":"10.1007\/s13311-013-0206-5_bib30","first-page":"18","article-title":"The epigenotype","volume":"1","author":"Waddington","year":"1942","journal-title":"Endeavour"},{"key":"10.1007\/s13311-013-0206-5_bib31","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.cell.2007.02.006","article-title":"Epigenetics: a landscape takes shape","volume":"128","author":"Goldberg","year":"2007","journal-title":"Cell"},{"key":"10.1007\/s13311-013-0206-5_bib32","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/ncpneuro0199","article-title":"Mechanisms of disease: Histone modifications in Huntington's disease","volume":"2","author":"Sadri-Vakili","year":"2006","journal-title":"Nat Clin Pract Neurol"},{"key":"10.1007\/s13311-013-0206-5_bib33","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/321209a0","article-title":"CpG-rich islands and the function of DNA methylation","volume":"321","author":"Bird","year":"1986","journal-title":"Nature"},{"key":"10.1007\/s13311-013-0206-5_bib34","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1517\/14728214.10.2.345","article-title":"Emerging chemotherapeutic strategies for Huntinton's disease","volume":"10","author":"Ryu","year":"2005","journal-title":"Expert Opin Emerg Drugs"},{"key":"10.1007\/s13311-013-0206-5_bib35","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1002\/j.1460-2075.1992.tb05055.x","article-title":"Repression of genes by DNA methylation depends on CpG density and promoter strength: Evidence for involvement of a methyl-CpG binding protein","volume":"11","author":"Boyes","year":"1992","journal-title":"EMBO J"},{"key":"10.1007\/s13311-013-0206-5_bib36","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/0092-8674(92)90610-O","article-title":"Purification, sequence, and cellular localization of a novel chromosomal protein that binds to methylated DNA","volume":"69","author":"Lewis","year":"1992","journal-title":"Cell"},{"key":"10.1007\/s13311-013-0206-5_bib37","doi-asserted-by":"crossref","first-page":"7587","DOI":"10.1128\/MCB.21.22.7587-7600.2001","article-title":"Reduced rates of gene loss, gene silencing, and gene mutation in Dnmt1-deficient embryonic stem cells","volume":"21","author":"Chan","year":"2001","journal-title":"Mol Cell Biol"},{"key":"10.1007\/s13311-013-0206-5_bib38","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1523\/JNEUROSCI.21-03-00788.2001","article-title":"DNA hypomethylation perturbs the function and survival of CNS neurons in postnatal animals","volume":"21","author":"Fan","year":"2001","journal-title":"J Neurosci"},{"key":"10.1007\/s13311-013-0206-5_bib39","doi-asserted-by":"crossref","first-page":"8862","DOI":"10.1128\/MCB.24.20.8862-8871.2004","article-title":"Severe global DNA hypomethylation blocks differentiation and induces histone hyperacetylation in embryonic stem cells","volume":"24","author":"Jackson","year":"2004","journal-title":"Mol Cell Biol"},{"key":"10.1007\/s13311-013-0206-5_bib40","doi-asserted-by":"crossref","first-page":"27915","DOI":"10.1074\/jbc.M312823200","article-title":"DNA methyltransferase 1 knock down induces gene expression by a mechanism independent of DNA methylation and histone deacetylation","volume":"279","author":"Milutinovic","year":"2004","journal-title":"J Biol Chem"},{"key":"10.1007\/s13311-013-0206-5_bib41","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1093\/nar\/gkm118","article-title":"Epigenetic disruption of ribosomal RAN genes and nucleolar architecture in DNA methyltransferase 1 (Dnmt1) deficient cells","volume":"35","author":"Espada","year":"2007","journal-title":"Nucleic Acids Res"},{"key":"10.1007\/s13311-013-0206-5_bib42","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1101\/gad.927301","article-title":"Transcription regulation by histone methylation: interplay between different covalent modifications of the core histone tails","volume":"15","author":"Zhang","year":"2001","journal-title":"Genes Dev"},{"key":"10.1007\/s13311-013-0206-5_bib43","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/nrg2008","article-title":"Heterochromatin revisited","volume":"8","author":"Grewal","year":"2007","journal-title":"Nat Rev Genet"},{"key":"10.1007\/s13311-013-0206-5_bib44","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.1073\/pnas.1221292110","article-title":"Extensive changes in DNA methylation are associated with expression of mutant huntingtin","volume":"110","author":"Ng","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1007\/s13311-013-0206-5_bib45","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s12017-013-8219-0","article-title":"Increased 5-methylcytosine and decreased 5-hydroxymethylcytosine levels are associated with reduced striatal A(2A)R levels in Huntington's disease","volume":"15","author":"Villar-Men\u00e9ndez","year":"2013","journal-title":"Neuromolecular Med"},{"key":"10.1007\/s13311-013-0206-5_bib46","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/nrneurol.2013.23","article-title":"Neurodegenerative disease: Altered DNA methylation and RNA splicing could be key mechanisms in Huntington disease","volume":"9","author":"Wood","year":"2013","journal-title":"Nat Rev Neurol"},{"key":"10.1007\/s13311-013-0206-5_bib47","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.ab.2013.01.035","article-title":"A novel method for detecting 7-methyl guanine reveals aberrant methylation levels in Huntington disease","volume":"436","author":"Thomas","year":"2013","journal-title":"Anal Biochem"},{"key":"10.1007\/s13311-013-0206-5_bib48","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1038\/sj.bjc.6601575","article-title":"Linking the epigenetic \u2018language\u2019 of covalent histone modifications to cancer","volume":"90","author":"Hake","year":"2004","journal-title":"Br J Cancer"},{"key":"10.1007\/s13311-013-0206-5_bib49","doi-asserted-by":"crossref","first-page":"373","DOI":"10.3233\/JAD-2010-100303","article-title":"Alzheimer's disease: the quest to understand complexity","volume":"21","author":"Marques","year":"2010","journal-title":"J Alzheimers Dis"},{"key":"10.1007\/s13311-013-0206-5_bib50","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.pneurobio.2010.01.002","article-title":"Epigenetic regulation in the pathophysiology of Alzheimer's disease","volume":"90","author":"Chouliaras","year":"2010","journal-title":"Prog Neurobiol"},{"key":"10.1007\/s13311-013-0206-5_bib51","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/S0092-8674(02)00798-5","article-title":"Histone methylation: dynamic or static?","volume":"109","author":"Bannister","year":"2002","journal-title":"Cell"},{"key":"10.1007\/s13311-013-0206-5_bib52","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1038\/nature01411","article-title":"Controlling the double helix","volume":"421","author":"Felsenfeld","year":"2003","journal-title":"Nature"},{"key":"10.1007\/s13311-013-0206-5_bib53","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/nrg2341","article-title":"DNA methylation landscapes: provocative insights from epigenomics","volume":"9","author":"Suzuki","year":"2008","journal-title":"Nat Rev Genet"},{"key":"10.1007\/s13311-013-0206-5_bib54","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1126\/science.1063127","article-title":"Translating the histone code","volume":"293","author":"Jenuwein","year":"2001","journal-title":"Science"},{"key":"10.1007\/s13311-013-0206-5_bib55","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/j.neuron.2004.05.021","article-title":"Chromatin acetylation, memory, and LTP are impaired in CBP+\/\u2212 mice: a model for the cognitive deficit in Rubinstein-Taybi syndrome and its amelioration","volume":"42","author":"Alarc\u00f3n","year":"2004","journal-title":"Neuron"},{"key":"10.1007\/s13311-013-0206-5_bib56","doi-asserted-by":"crossref","first-page":"10335","DOI":"10.1523\/JNEUROSCI.2599-04.2004","article-title":"Chemotherapy for the brain: the antitumor antibiotic mithramycin prolongs survival in a mouse model of Huntington's disease","volume":"24","author":"Ferrante","year":"2004","journal-title":"J Neurosci"},{"key":"10.1007\/s13311-013-0206-5_bib57","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/35099568","article-title":"Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila","volume":"413","author":"Steffan","year":"2001","journal-title":"Nature"},{"key":"10.1007\/s13311-013-0206-5_bib58","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1097\/00001756-200303240-00007","article-title":"Inducible PC12 cell model Huntington's disease shows toxicity and decreased histone acetylation","volume":"14","author":"Igarashi","year":"2003","journal-title":"Neuroreport"},{"key":"10.1007\/s13311-013-0206-5_bib59","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1093\/hmg\/ddm078","article-title":"Histones associated with downregulated genes are hypo-acetylated in Huntington's disease models","volume":"16","author":"Sadri-Vakili","year":"2007","journal-title":"Hum Mol Genet"},{"key":"10.1007\/s13311-013-0206-5_bib60","doi-asserted-by":"crossref","first-page":"15564","DOI":"10.1073\/pnas.0804249105","article-title":"The HDAC inhibitor 4b ameliorates the disease phenotype and transcriptional abnormalities in Huntington's disease transgenic mice","volume":"105","author":"Thomas","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1007\/s13311-013-0206-5_bib61","doi-asserted-by":"crossref","first-page":"e41423","DOI":"10.1371\/journal.pone.0041423","article-title":"Genome-wide histone acetylation is altered in a transgenic mouse model of Huntington's disease","volume":"7","author":"McFarland","year":"2012","journal-title":"PLoS One"},{"key":"10.1007\/s13311-013-0206-5_bib62","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/384641a0","article-title":"The CBP co-activator is a histone acetyltransferase","volume":"384","author":"Bannister","year":"1996","journal-title":"Nature"},{"key":"10.1007\/s13311-013-0206-5_bib63","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/j.neuron.2004.06.002","article-title":"CBP histone acetyltransferase activity is a critical component of memory consolidation","volume":"42","author":"Korzus","year":"2004","journal-title":"Neuron"},{"key":"10.1007\/s13311-013-0206-5_bib64","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/BF02736773","article-title":"Hypomethylation of the amyloid precursor protein gene in the brain of an Alzheimer's disease patient","volume":"6","author":"West","year":"1995","journal-title":"J Mol Neurosci"},{"key":"10.1007\/s13311-013-0206-5_bib65","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1074\/jbc.M410210200","article-title":"Neuroprotective effects of phenylbutyrate in the N171-82Q transgenic mouse model of Huntington's disease","volume":"280","author":"Gardian","year":"2005","journal-title":"J Biol Chem"},{"key":"10.1007\/s13311-013-0206-5_bib66","doi-asserted-by":"crossref","first-page":"19176","DOI":"10.1073\/pnas.0606373103","article-title":"ESET\/SETDB1 gene expression and histone H3(K9) trimethylation in Huntington's disease","volume":"103","author":"Ryu","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1007\/s13311-013-0206-5_bib67","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1101\/lm.656907","article-title":"Transgenic mice expressing an inhibitory truncated form of p300 exhibit long-term memory deficits","volume":"14","author":"Oliveira","year":"2007","journal-title":"Learn Mem"},{"key":"10.1007\/s13311-013-0206-5_bib68","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1093\/hmg\/ddn067","article-title":"Monoallele deletion of CBP leads to pericentromeric heterochromatin condensation through ESET expression and histone H3(K9) methylation","volume":"17","author":"Lee","year":"2008","journal-title":"Hum Mol Genet"},{"key":"10.1007\/s13311-013-0206-5_bib69","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1007\/s00401-013-1103-z","article-title":"Epigenetic regulation of cholinergic receptor M1 (CHRM1) by histone H3K9me3 impairs Ca(2+) signaling in Huntington's disease","volume":"125","author":"Lee","year":"2013","journal-title":"Acta Neuropathol"},{"key":"10.1007\/s13311-013-0206-5_bib70","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1093\/hmg\/ddm064","article-title":"Modulation of nucleosome dynamics in Huntington's disease","volume":"16","author":"Stack","year":"2007","journal-title":"Hum Mol Genet"},{"key":"10.1007\/s13311-013-0206-5_bib71","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1091\/mbc.e04-11-0997","article-title":"Differential subnuclear localization and replication timing of histone H3 lysine 9 methylation states","volume":"16","author":"Wu","year":"2005","journal-title":"Mol Biol Cell"},{"key":"10.1007\/s13311-013-0206-5_bib72","doi-asserted-by":"crossref","first-page":"2608","DOI":"10.1073\/pnas.88.6.2608","article-title":"Distinct muscarinic receptors inhibit release of GABA and excitatory amino acids in mammalian brain","volume":"88","author":"Sugita","year":"1991","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1007\/s13311-013-0206-5_bib73","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1126\/science.3037705","article-title":"Identification of a family of muscarinic acetylcholine receptor genes","volume":"237","author":"Bonner","year":"1897","journal-title":"Science"},{"key":"10.1007\/s13311-013-0206-5_bib74","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1146\/annurev.pa.30.040190.003221","article-title":"Muscarinic receptor subtypes","volume":"30","author":"Hulme","year":"1990","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1007\/s13311-013-0206-5_bib75","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1615\/CritRevNeurobiol.v10.i1.40","article-title":"Molecular biology of muscarinic acetylcholine receptors","volume":"10","author":"Wess","year":"1996","journal-title":"Crit Rev Neurobiol"},{"key":"10.1007\/s13311-013-0206-5_bib76","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/S0166-2236(99)01501-5","article-title":"Acetylcholine-mediated modulation of striatal function","volume":"23","author":"Calabresi","year":"2000","journal-title":"Trends Neurosci"},{"key":"10.1007\/s13311-013-0206-5_bib77","doi-asserted-by":"crossref","first-page":"6480","DOI":"10.1073\/pnas.95.11.6480","article-title":"Altered brain neurotransmitter receptors in transgenic mice expressing a portion of an abnormal human Huntington disease gene","volume":"95","author":"Cha","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1007\/s13311-013-0206-5_bib78","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.neuron.2006.04.010","article-title":"Dopaminergic control of corticostriatal long-term synaptic depression in medium spiny neurons is mediated by cholinergic interneurons","volume":"50","author":"Wang","year":"2006","journal-title":"Neuron"},{"key":"10.1007\/s13311-013-0206-5_bib79","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.neuron.2006.04.023","article-title":"Striatal D2 receptors and LTD: yes, but not where you thought they were","volume":"50","author":"Wilson","year":"2006","journal-title":"Neuron"},{"key":"10.1007\/s13311-013-0206-5_bib80","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.cell.2008.10.053","article-title":"Posttranscriptional crossregulation between Drosha and DGCR8","volume":"136","author":"Han","year":"2009","journal-title":"Cell"},{"key":"10.1007\/s13311-013-0206-5_bib81","doi-asserted-by":"crossref","first-page":"3016","DOI":"10.1101\/gad.1262504","article-title":"The Drosha-DGCR8 complex in primary microRNA processing","volume":"18","author":"Han","year":"2004","journal-title":"Genes Dev"},{"key":"10.1007\/s13311-013-0206-5_bib82","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.nbd.2007.11.001","article-title":"A microRNA-based gene dysregulation pathway in Huntington's disease","volume":"29","author":"Johnson","year":"2008","journal-title":"Neurobiol Dis"},{"key":"10.1007\/s13311-013-0206-5_bib83","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.expneurol.2010.10.012","article-title":"Altered microRNA regulation in Huntington's disease models","volume":"227","author":"Lee","year":"2011","journal-title":"Exp Neurol"},{"key":"10.1007\/s13311-013-0206-5_bib84","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.expneurol.2011.07.005","article-title":"New insights into non-coding RNA networks in Huntington's disease","volume":"231","author":"Buckley","year":"2011","journal-title":"Exp Neurol"},{"key":"10.1007\/s13311-013-0206-5_bib85","doi-asserted-by":"crossref","first-page":"e23837","DOI":"10.1371\/journal.pone.0023837","article-title":"Regulation of miR-146a by RelA\/NFkB and p53 in STHdhQ111\/HdhQ111 cells, a cell model of Huntington's disease","volume":"6","author":"Ghose","year":"2011","journal-title":"PLos One"},{"key":"10.1007\/s13311-013-0206-5_bib86","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.neuron.2005.06.005","article-title":"p53 mediates cellular dysfunction and behavioral abnormalities in Huntington's disease","volume":"47","author":"Bae","year":"2005","journal-title":"Neuron"},{"key":"10.1007\/s13311-013-0206-5_bib87","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1093\/jnci\/92.15.1210","article-title":"Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells","volume":"92","author":"Marks","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"10.1007\/s13311-013-0206-5_bib88","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1093\/bfgp\/ell032","article-title":"Simple histone acetylation plays a complex role in the regulation of gene expression","volume":"5","author":"Fukuda","year":"2006","journal-title":"Brief Funct Genomic Proteomic"},{"key":"10.1007\/s13311-013-0206-5_bib89","doi-asserted-by":"crossref","first-page":"3179","DOI":"10.1111\/j.1460-9568.2004.03765.x","article-title":"Benefit of valpronic acid in suppressing disease progression of ALS model mice","volume":"20","author":"Sugai","year":"2004","journal-title":"Eur J Neurosci"},{"key":"10.1007\/s13311-013-0206-5_bib90","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.jneuroim.2005.02.022","article-title":"Transcriptional therapy with the histone deacetylase inhibitor trichostatin A ameliorates experimental autoimmune encephalomyelitis","volume":"164","author":"Camelo","year":"2005","journal-title":"J Neuroimmunol"},{"key":"10.1007\/s13311-013-0206-5_bib91","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1073\/pnas.0437870100","article-title":"Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease","volume":"100","author":"Hockly","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1007\/s13311-013-0206-5_bib92","doi-asserted-by":"crossref","first-page":"e27746","DOI":"10.1371\/journal.pone.0027746","article-title":"SAHA decreases HDAC2 and 4 levels in vivo and improves molecular phenotypes in the R6\/2 mouse model of Huntington's disease","volume":"6","author":"Mielcarek","year":"2011","journal-title":"PLos One"},{"key":"10.1007\/s13311-013-0206-5_bib93","doi-asserted-by":"crossref","first-page":"15179","DOI":"10.1073\/pnas.261400698","article-title":"Histone deacetylase inhibitors reduce polyglutamine toxicity","volume":"98","author":"McCampbell","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1007\/s13311-013-0206-5_bib94","doi-asserted-by":"crossref","first-page":"9418","DOI":"10.1523\/JNEUROSCI.23-28-09418.2003","article-title":"Histone deacetylase inhibition by sodium butyrate chemotherapy ameliorates the neurodegenerative phenotype in Huntington's disease mice","volume":"23","author":"Ferrante","year":"2003","journal-title":"J Neurosci"},{"key":"10.1007\/s13311-013-0206-5_bib95","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/0277-5379(87)90109-X","article-title":"Clinical pharmacology of sodium butyrate in patients with acute leukemia","volume":"23","author":"Miller","year":"1987","journal-title":"Eur J Cancer Clin Oncol"},{"key":"10.1007\/s13311-013-0206-5_bib96","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/0009-8981(89)90231-3","article-title":"Pharmacokinetic study of butyric acid administered in vivo as sodium and arginine butyrate salt","volume":"181","author":"Daniel","year":"1989","journal-title":"Clin Chim Acta"},{"key":"10.1007\/s13311-013-0206-5_bib97","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/s002800050922","article-title":"Plasma pharmacokinetics of butyrate after intravenous administration of sodium, butyrate or oral administration of tributyrin or sodium butyrate to mice and rats","volume":"43","author":"Egorin","year":"1999","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1007\/s13311-013-0206-5_bib98","doi-asserted-by":"crossref","first-page":"3874","DOI":"10.4049\/jimmunol.170.7.3874","article-title":"Sodium phenylacetate inhibits adoptive transfer of experimental allergic encephaplomyelitis in SJL\/J mice at multiple steps","volume":"170","author":"Dasgupta","year":"2003","journal-title":"J immunol"},{"key":"10.1007\/s13311-013-0206-5_bib99","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1002\/mds.21632","article-title":"Sodium phenylbutyrate in Huntington's disease: a dose-finding study","volume":"22","author":"Hogarth","year":"2007","journal-title":"Mov Disord"},{"key":"10.1007\/s13311-013-0206-5_bib100","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.ab.2010.01.010","article-title":"Identification of phenylbutyrate-generated metabolites in Huntington disease patients using parallel liquid chromatography\/electrochemical array\/mass spectrometry and off-line tandem mass spectrometry","volume":"399","author":"Ebbel","year":"2010","journal-title":"Anal Biochem"},{"key":"10.1007\/s13311-013-0206-5_bib101","doi-asserted-by":"crossref","first-page":"5280","DOI":"10.1093\/hmg\/dds379","article-title":"Selective histone deacetylase (HDAC) inhibition imparts beneficial effects in Huntington's disease mice: implications for the ubiquitin-proteasomal and autophagy systems","volume":"21","author":"Jia","year":"2012","journal-title":"Hum Mol Genet"},{"key":"10.1007\/s13311-013-0206-5_bib102","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.nbd.2012.01.016","article-title":"Histone deacetylase (HDAC) inhibitors targeting HDAC3 and HDAC1 ameliorate polyglutamine-elicited phenotypes in model systems of Huntington's disease","volume":"46","author":"Jia","year":"2012","journal-title":"Neurobiol Dis"},{"key":"10.1007\/s13311-013-0206-5_bib103","doi-asserted-by":"crossref","first-page":"17141","DOI":"10.1073\/pnas.1104409108","article-title":"Transcriptional modulator H2A histone family, member Y (H2AFY) marks Huntington disease activity in man and mouse","volume":"108","author":"Hu","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1007\/s13311-013-0206-5_bib104","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S1074-5521(96)90262-8","article-title":"Deciphering the biosynthetic origin of the aglycone of the aureolic acid group of anti-tumor agents","volume":"3","author":"Blanco","year":"1996","journal-title":"Chem Biol"},{"key":"10.1007\/s13311-013-0206-5_bib105","first-page":"179","article-title":"Pathogenesis and management of cancer associated hypercalcaemia","volume":"21","author":"Ralston","year":"1994","journal-title":"Cancer Surv"},{"key":"10.1007\/s13311-013-0206-5_bib106","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1002\/1097-0282(2000)56:2<85::AID-BIP1054>3.0.CO;2-7","article-title":"Structural basis of DNA recognition by anticancer antibiotics, chromomycin A3, and mithramycin: roles of minor groove width and ligand flexibility","volume":"56","author":"Chakrabarti","year":"2001","journal-title":"Biopolymers"},{"key":"10.1007\/s13311-013-0206-5_bib107","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1097\/00000441-198907000-00006","article-title":"Metastatic carcinoma of unknown primary: complete response to second-line treatment with plicamycin","volume":"298","author":"Hescock","year":"1989","journal-title":"Am J Med Sci"},{"key":"10.1007\/s13311-013-0206-5_bib108","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1007\/s004380050960","article-title":"Analysis of two chromosomal region adjacent to genes for a Type II polyketide synthase involved in the biosynthesis of the antitumor polyketide mithramycin in Streptomyces argillaceus","volume":"261","author":"Prado","year":"1999","journal-title":"Mol Gen Genet"},{"key":"10.1007\/s13311-013-0206-5_bib109","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1097\/00003086-197709000-00012","article-title":"Treatment of Paget's disease of bone with mithramycin","volume":"127","author":"Ryan","year":"1977","journal-title":"Clin Orthop"},{"key":"10.1007\/s13311-013-0206-5_bib110","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/S0022-5347(17)61046-2","article-title":"Mithramycin therapy in testicular cancer","volume":"107","author":"Kennedy","year":"1972","journal-title":"J Urol"},{"key":"10.1007\/s13311-013-0206-5_bib111","doi-asserted-by":"crossref","first-page":"24989","DOI":"10.1074\/jbc.270.42.24989","article-title":"Functional analyses of the transcription factor Sp4 reveal properties distinct from Sp1 and Sp3","volume":"270","author":"Hagen","year":"1995","journal-title":"J Biol Chem"},{"key":"10.1007\/s13311-013-0206-5_bib112","first-page":"1841","article-title":"Differential transcriptional regulation of c-myc promoter through the same DNA binding sites targeted by Sp1-like proteins","volume":"10","author":"Majello","year":"1995","journal-title":"Oncogene"},{"key":"10.1007\/s13311-013-0206-5_bib113","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1002\/ana.71","article-title":"Sequence-selective DNA binding drugs mithramycin A and chromomycin A3 are potent inhibitors of neuronal apoptosis induced by oxidative stress and DNA damage in cortical neurons","volume":"49","author":"Chatterjee","year":"2001","journal-title":"Ann Neurol"},{"key":"10.1007\/s13311-013-0206-5_bib114","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1038\/gt.2011.170","article-title":"Using non-coding small RNAs to develop therapies for Huntington's disease","volume":"18","author":"Zhang","year":"2011","journal-title":"Gene Ther"},{"key":"10.1007\/s13311-013-0206-5_bib115","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1038\/nbt.1539","article-title":"Allele-specific silencing of mutant huntingtin and ataxin-3 genes by targeting expanded CAG repeats in mRNAs","volume":"27","author":"Hu","year":"2009","journal-title":"Nat Biotechnol"},{"key":"10.1007\/s13311-013-0206-5_bib116","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.expneurol.2009.03.004","article-title":"A majority of Huntington's disease patients may be treatable by individualized allele-specific RNA interference","volume":"217","author":"Lombardi","year":"2009","journal-title":"Exp Neurol"},{"key":"10.1007\/s13311-013-0206-5_bib117","doi-asserted-by":"crossref","first-page":"5820","DOI":"10.1073\/pnas.0501507102","article-title":"RNA interference improves motor and neuropathological abnormalities in a Huntington's disease mouse model","volume":"102","author":"Harper","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1007\/s13311-013-0206-5_bib118","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1038\/mt.2008.50","article-title":"AAV vector-mediated RNAi of mutant huntingtin expression is neuroprotective in a novel genetic rat model of Huntington's disease","volume":"16","author":"Franich","year":"2008","journal-title":"Mol Ther"},{"key":"10.1007\/s13311-013-0206-5_bib119","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.ymthe.2005.05.006","article-title":"Intrastriatal rAAV-mediated delivery of anti-huntingtin shRNAs induces partial reversal of disease progression in R6\/1 Huntington's disease transgenic mice","volume":"12","author":"Rodriguez-Lebron","year":"2005","journal-title":"Mol Ther"},{"key":"10.1007\/s13311-013-0206-5_bib120","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.bbrc.2006.02.141","article-title":"rAAV-mediated shRNA ameliorated neuropathology in Huntington disease model mouse","volume":"343","author":"Machida","year":"2006","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1007\/s13311-013-0206-5_bib121","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1089\/hum.2006.160","article-title":"High capacity adenoviral vector-mediated reduction of huntingtin aggregate load in vitro and in vivo","volume":"18","author":"Huang","year":"2007","journal-title":"Hum Gene Ther"},{"key":"10.1007\/s13311-013-0206-5_bib122","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1002\/ana.21569","article-title":"Sustained effects of nonallele-specific Huntingtin silencing","volume":"65","author":"Drouet","year":"2009","journal-title":"Ann Neurol"},{"key":"10.1007\/s13311-013-0206-5_bib123","doi-asserted-by":"crossref","first-page":"5868","DOI":"10.1073\/pnas.0801775105","article-title":"Artificial miRNAs mitigate shRNA-mediated toxicity in the brain: implications for the therapeutic development of RNAi","volume":"105","author":"McBride","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1007\/s13311-013-0206-5_bib124","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1038\/mt.2009.17","article-title":"Nonallele-specific silencing of mutant and wild-type huntingtin demonstrates therapeutic efficacy in Huntington's disease mice","volume":"17","author":"Boudreau","year":"2009","journal-title":"Mol Ther"},{"key":"10.1007\/s13311-013-0206-5_bib125","doi-asserted-by":"crossref","first-page":"17204","DOI":"10.1073\/pnas.0708285104","article-title":"Therapeutic silencing of mutant huntingtin with siRNA attenuates striatal and cortical neuropathology and behavioral deficits","volume":"104","author":"Difiglia","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1007\/s13311-013-0206-5_bib126","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/j.cell.2012.08.002","article-title":"Single-stranded RNAs use RNAi to potently and allele-selectively inhibit mutant huntingtin expression","volume":"150","author":"Yu","year":"2012","journal-title":"Cell"},{"key":"10.1007\/s13311-013-0206-5_bib127","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S1566-2772(03)00059-8","article-title":"Mechanisms of transcriptional dysregulation in Huntington's disease","volume":"3","author":"Luthi-Carter","year":"2003","journal-title":"Clin Neurosci Res"},{"key":"10.1007\/s13311-013-0206-5_bib128","first-page":"3597","article-title":"Histone deacetylase inhibitors prevent oxidative neuronal death independent of expanded polyglutamine repeats via an Sp1-dependent pathway","volume":"23","author":"Ryu","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1007\/s13311-013-0206-5_bib129","doi-asserted-by":"crossref","first-page":"3571","DOI":"10.1523\/JNEUROSCI.0037-07.2007","article-title":"Histone deacetylase 6 inhibition compensates for the transport deficit in Huntington's disease by increasing tubulin acetylation","volume":"27","author":"Dompierre","year":"2007","journal-title":"J Neurosci"},{"key":"10.1007\/s13311-013-0206-5_bib130","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1159\/000022023","article-title":"Differential chromosome sensitivity to 5-azacytidine in Alzheimer' disease","volume":"44","author":"Payao","year":"1998","journal-title":"Gerontology"}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-013-0206-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13311-013-0206-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923016616?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923016616?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-013-0206-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T07:10:12Z","timestamp":1761808212000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878747923016616"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10]]},"references-count":130,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,10]]}},"alternative-id":["S1878747923016616"],"URL":"https:\/\/doi.org\/10.1007\/s13311-013-0206-5","relation":{},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2013,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Epigenetic Mechanisms of Neurodegeneration in Huntington's Disease","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1007\/s13311-013-0206-5","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 The American Society for Experimental NeuroTherapeutics, Inc. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}